NVO

Novo Nordisk

Exchange: NYSESector: HealthcareIndustry: Biotechnology

Values in USD · ADR · Reports in DKK

Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.

Current Price

—

GoodMoat Value

$87.03

Profile

Valuation (TTM)

Market Cap—

P/E—

EV—

P/B—

Shares Out—

P/Sales—

Revenue—

EV/EBITDA—

Novo Nordisk (NVO) Valuation

NVO Fair Value Estimate

$87.03

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

NVO Valuation Metrics

FCF—

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Fair Value Models

Graham Number, PEG-based, and Earnings-based models

View Fair Value →

NVO Valuation & Fair Value Analysis

Novo Nordisk (NVO) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Novo Nordisk is $87.03.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Novo Nordisk's intrinsic value.